LitAlert ~~ GeneLit.com

    • PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis.
    • Yan F, Jiang Q, He M, Shen P.
    • Future Oncol. 2021 Mar 31. doi: 10.2217/fon-2020-1175. Epub ahead of print.
    • Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.
    • Holanek M, Selingerova I, Bilek O, Kazda T, Fabian P, Foretova L, Zvarikova M, Obermannova R, Kolouskova I, Coufal O, Petrakova K, Marek Svoboda M, Poprach A.
    • Cancers (Basel). 2021 Mar 30;13(7):E1586. doi: 10.3390/cancers13071586.
    • Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival.
    • Earl J, Barreto E, Castillo ME, Fuentes R, Rodríguez-Garrote M, Ferreiro R, Reguera P, Muñoz G, Garcia-Seisdedos D, Villalón López J, Sainz Jr B, Malats N, Carrato A.
    • Cancers (Basel). 2021 Mar 31;13(7):E1612. doi: 10.3390/cancers13071612.
    • Selective killing of homologous recombination-deficient cancer cell lines by inhibitors of the RPA:RAD52 protein-protein interaction.
    • Al-Mugotir M, Lovelace JJ, George J, Bessho M, Pal D, Struble L, Kolar C, Rana S, Natarajan A, Bessho T, Borgstahl GEO.
    • PLoS One. 2021 Mar 30;16(3):e0248941. doi: 10.1371/journal.pone.0248941.
    • LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair.
    • Chen L, Hou J, Zeng X, Guo Q, Deng M, Kloeber JA, Tu X, Zhao F, Wu Z, Huang J, Luo K, Kim W, Lou Z.
    • Clin Transl Med. 2021 Mar;11(3):e341. doi: 10.1002/ctm2.341.
    • New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
    • Gervas P, Molokov A, Ivanova A, Panferova Y, Kiselev A, Chernyshova A, Pisareva L, Choynzonov E, Cherdyntseva N.
    • Exp Oncol. 2021 Mar;43(1):52-55.
    • Prevalence of BRCA1 and BRCA2 genes promoter hypermethylation in breast cancer tissue.
    • Lobanova OE, Rossokha ZI, Medvedieva NL, Cheshuk VE, Vereshchako RI, Vershyhora VO, Fishchuk LY, Zakhartseva LM, Gorovenko NG.
    • Exp Oncol. 2021 Mar;43(1):56-60.